Inipharm Inc. has divulged thiazoles/isothiazoles acting as 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13) inhibitors reported to be useful for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, cirrhosis, alcoholic liver disease, drug-induced liver injury and portal hypertension.

Stanford University and Acurex Therapeutics Corp. have discovered voltage-dependent T-type calcium channel subunit α-1H (Cav3.2) blockers reported to be useful for the treatment of neurodegeneration.

Standigm Inc. has disclosed leucine-rich repeat kinase 2 (LRRK2), particularly LRRK2 G2019S mutant, inhibitors reported to be useful for the treatment of cancer, neurodegeneration, rheumatoid arthritis, tuberculosis, axial spondyloarthritis, radiographic (ankylosing spondylitis), Crohn's disease and dyskinesia.

Immunic AG has disclosed deuterated dihydroorotate dehydrogenase (DHODH) inhibitors reported to be useful for the treatment of Crohn's disease, influenza, lupus erythematosus, multiple sclerosis, psoriasis, rheumatoid arthritis, SARS-CoV-2 infection (COVID-19) and cancer.

Sumitomo Pharma Co. Ltd. has divulged bicyclic pyridine derivatives acting as trace amine-associated receptor 1 (TAAR1) agonists reported to be useful for the treatment of neurological and psychiatric disorders.

The FDA has cleared Brexogen Inc. to initiate a phase I trial of BRE-AD01, an exosome-based therapy for atopic dermatitis.

Eccogene (Shanghai) Co. Ltd. has received FDA clearance to begin a phase I study of its glucagon-like peptide 1 (GLP-1) receptor agonist ECC-5004 for type 2 diabetes.

Exelixis Inc. and Sairopa BV have entered into an exclusive clinical development and option agreement for ADU-1805, a potentially best-in-class monoclonal antibody that targets SIRPα.